Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2026)

Mirum Pharmaceuticals' Receivables history runs 6 years deep, the most recent figure standing at $133.1 million for Q1 2026.

• On a quarterly basis, Receivables rose 38.87% year-over-year to $133.1 million in Q1 2026; TTM through Mar 2026 was $133.1 million, a 38.87% increase from a year earlier, with the FY2025 full-year figure at $123.3 million, up 57.54% from the prior year.
• Receivables advanced to $133.1 million in Q1 2026 per MIRM's latest filing, from $107.1 million in the prior quarter.
• Across five years, Receivables topped out at $133.1 million in Q1 2026 and bottomed at $7.9 million in Q1 2022.
• The 5-year median for Receivables is $57.7 million (2024), against an average of $58.9 million.
• Across the five-year window, Receivables surged 3984.25% in 2022 and rose 15.18% in 2024, its largest moves.
• Year by year, Receivables stood at $24.0 million in 2022, then jumped by 183.27% to $68.0 million in 2023, then grew by 15.18% to $78.3 million in 2024, then surged by 36.85% to $107.1 million in 2025, then gained by 24.25% to $133.1 million in 2026.
• Per Business Quant, the three latest MIRM Receivables figures stand at $133.1 million (Q1 2026), $107.1 million (Q3 2025), and $106.8 million (Q2 2025).